521 related articles for article (PubMed ID: 32985336)
21. Effect of antibiotic to induce Clostridioides difficile-susceptibility and infectious strain in a mouse model of Clostridioides difficile infection and recurrence.
Castro-Córdova P; Díaz-Yáñez F; Muñoz-Miralles J; Gil F; Paredes-Sabja D
Anaerobe; 2020 Apr; 62():102149. PubMed ID: 31940467
[TBL] [Abstract][Full Text] [Related]
22. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
[No Abstract] [Full Text] [Related]
23.
Collins DA; Sohn KM; Wu Y; Ouchi K; Ishii Y; Elliott B; Riley TV; Tateda K;
Emerg Microbes Infect; 2020; 9(1):42-52. PubMed ID: 31873046
[No Abstract] [Full Text] [Related]
24. Antimicrobial Activity of Tannic Acid
Wang W; Cao J; Yang J; Niu X; Liu X; Zhai Y; Qiang C; Niu Y; Li Z; Dong N; Wen B; Ouyang Z; Zhang Y; Li J; Zhao M; Zhao J
Microbiol Spectr; 2023 Feb; 11(1):e0261822. PubMed ID: 36537806
[TBL] [Abstract][Full Text] [Related]
25. Frontiers in antibiotic alternatives for
Phanchana M; Harnvoravongchai P; Wongkuna S; Phetruen T; Phothichaisri W; Panturat S; Pipatthana M; Charoensutthivarakul S; Chankhamhaengdecha S; Janvilisri T
World J Gastroenterol; 2021 Nov; 27(42):7210-7232. PubMed ID: 34876784
[No Abstract] [Full Text] [Related]
26. Antibiotic Exposure and Risk for Hospital-Associated Clostridioides difficile Infection.
Webb BJ; Subramanian A; Lopansri B; Goodman B; Jones PB; Ferraro J; Stenehjem E; Brown SM
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964789
[No Abstract] [Full Text] [Related]
27. Anti-virulence strategies for
Stewart D; Anwar F; Vedantam G
Gut Microbes; 2020 Nov; 12(1):1802865. PubMed ID: 33092487
[No Abstract] [Full Text] [Related]
28. Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.
Sholeh M; Krutova M; Forouzesh M; Mironov S; Sadeghifard N; Molaeipour L; Maleki A; Kouhsari E
Antimicrob Resist Infect Control; 2020 Sep; 9(1):158. PubMed ID: 32977835
[TBL] [Abstract][Full Text] [Related]
29. The CD27L and CTP1L endolysins targeting Clostridia contain a built-in trigger and release factor.
Dunne M; Mertens HD; Garefalaki V; Jeffries CM; Thompson A; Lemke EA; Svergun DI; Mayer MJ; Narbad A; Meijers R
PLoS Pathog; 2014 Jul; 10(7):e1004228. PubMed ID: 25058163
[TBL] [Abstract][Full Text] [Related]
30. Multicenter study of the epidemiology of Clostridioides difficile infection and recurrence in southern Brazil.
Maestri AC; Raboni SM; Morales HMP; Ferrari LF; Tuon FFB; Losso A; Marconi C; Nogueira KDS
Anaerobe; 2020 Aug; 64():102238. PubMed ID: 32717474
[TBL] [Abstract][Full Text] [Related]
31. Diversity, Dynamics and Therapeutic Application of
Nale JY; Thanki AM; Rashid SJ; Shan J; Vinner GK; Dowah ASA; Cheng JKJ; Sicheritz-Pontén T; Clokie MRJ
Viruses; 2022 Dec; 14(12):. PubMed ID: 36560776
[No Abstract] [Full Text] [Related]
32. Ursodeoxycholic Acid (UDCA) Mitigates the Host Inflammatory Response during Clostridioides difficile Infection by Altering Gut Bile Acids.
Winston JA; Rivera AJ; Cai J; Thanissery R; Montgomery SA; Patterson AD; Theriot CM
Infect Immun; 2020 May; 88(6):. PubMed ID: 32205405
[No Abstract] [Full Text] [Related]
33. New Host-Directed Therapeutics for the Treatment of Clostridioides difficile Infection.
Andersson JA; Peniche AG; Galindo CL; Boonma P; Sha J; Luna RA; Savidge TC; Chopra AK; Dann SM
mBio; 2020 Mar; 11(2):. PubMed ID: 32156806
[TBL] [Abstract][Full Text] [Related]
34. Phage therapy for
Fujimoto K; Uematsu S
Front Immunol; 2022; 13():1057892. PubMed ID: 36389774
[No Abstract] [Full Text] [Related]
35. Plasmid Acquisition Alters Vancomycin Susceptibility in Clostridioides difficile.
Pu M; Cho JM; Cunningham SA; Behera GK; Becker S; Amjad T; Greenwood-Quaintance KE; Mendes-Soares H; Jones-Hall Y; Jeraldo PR; Chen J; Dunny G; Patel R; Kashyap PC
Gastroenterology; 2021 Feb; 160(3):941-945.e8. PubMed ID: 33197449
[TBL] [Abstract][Full Text] [Related]
36. Characterization of two glycosyl hydrolases, putative prophage endolysins, that target Clostridium perfringens.
Swift SM; Waters JJ; Rowley DT; Oakley BB; Donovan DM
FEMS Microbiol Lett; 2018 Aug; 365(16):. PubMed ID: 30010898
[TBL] [Abstract][Full Text] [Related]
37. Omadacycline and
Garey KW; Rose W; Gunter K; Serio AW; Wilcox MH
Ann Pharmacother; 2023 Feb; 57(2):184-192. PubMed ID: 35656828
[TBL] [Abstract][Full Text] [Related]
38. A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity.
Gebhart D; Lok S; Clare S; Tomas M; Stares M; Scholl D; Donskey CJ; Lawley TD; Govoni GR
mBio; 2015 Mar; 6(2):. PubMed ID: 25805733
[TBL] [Abstract][Full Text] [Related]
39. Biofilms harbour Clostridioides difficile, serving as a reservoir for recurrent infection.
Normington C; Moura IB; Bryant JA; Ewin DJ; Clark EV; Kettle MJ; Harris HC; Spittal W; Davis G; Henn MR; Ford CB; Wilcox MH; Buckley AM
NPJ Biofilms Microbiomes; 2021 Feb; 7(1):16. PubMed ID: 33547298
[TBL] [Abstract][Full Text] [Related]
40. Metagenome Data on Intestinal Phage-Bacteria Associations Aids the Development of Phage Therapy against Pathobionts.
Fujimoto K; Kimura Y; Shimohigoshi M; Satoh T; Sato S; Tremmel G; Uematsu M; Kawaguchi Y; Usui Y; Nakano Y; Hayashi T; Kashima K; Yuki Y; Yamaguchi K; Furukawa Y; Kakuta M; Akiyama Y; Yamaguchi R; Crowe SE; Ernst PB; Miyano S; Kiyono H; Imoto S; Uematsu S
Cell Host Microbe; 2020 Sep; 28(3):380-389.e9. PubMed ID: 32652061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
